Pre-randomization Atrioventricular Interval Modulation Therapy (“AVIM Therapy”) set-up data from the MODERATO II randomized, prospective, ...

Oral MYC condensate modulator drives tumor regression and stasis in preclinical modelsDisruption of MYC condensates enables targeted inhibition ...

Marvell Technology Inc. has acquired plasmonics-based silicon photonic device maker Polariton Technologies. The move will strengthen Marvell’s optical technology portfolio, adding advanced modulation ...

Scientists have unveiled a breakthrough imaging method that can capture the hidden details of events unfolding in trillionths ...

SemiTech's fair value price target has been marked slightly higher, shifting from US$104.62 to US$105.54, a move of about 0.9%. That tweak lines up with a wave of Street research that has pushed ...

Marvell Technology acquired Polariton Technologies in a push to develop faster connectivity technology to support artificial-intelligence workloads.

Wi-Fi 7 benefits explained with faster speeds, lower latency, Multi-Link Operation, and better connectivity for gaming, ...

Researchers reported favorable safety and tolerability for CS1 after 12 months of treatment in patients with pulmonary arterial hypertension.

Mozart Therapeutics, the leading developer of CD8 Treg network modulators for the treatment of autoimmune disease, today ...

While the primary motor endpoint showed modest improvement, more notable effects were observed in non-motor domains.

The Phase II trial enrolled 129 participants, of whom 94% had relapsing remitting multiple sclerosis, and 6% had secondary ...

Complete and durable regression and anti-tumor immune memory following treatment with FHD-909 (LY4050784) in combination with an anti-PD-1 antibody in preclinical syngeneic mouse models ...